Assyro AI

Orange Book product · Brand (NDA)

TROKENDI XR

TOPIRAMATE

Brand (NDA)NDA 201635TE AB1RX SUPERNUS PHARMS

At a glance

Aug 16, 2013

Approved

Brand (NDA)

Application

AB1

TE code

20

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Aug 16, 2013

    13 yr ago

  2. Today

  3. Patent 10314790 expires

    Listed drug product patent expiration.

    Nov 16, 2027

    in 1 yr 5 mo

  4. Patent 10314790 expires

    Listed drug product patent expiration.

    Nov 16, 2027

    in 1 yr 5 mo

  5. Patent 8298580 expires

    Listed drug product patent expiration.

    Nov 16, 2027

    in 1 yr 5 mo

  6. Patent 8298580 expires

    Listed drug product patent expiration.

    Nov 16, 2027

    in 1 yr 5 mo

  7. Patent 8663683 expires

    Listed drug product patent expiration.

    Nov 16, 2027

    in 1 yr 5 mo

  8. Patent 8663683 expires

    Listed drug product patent expiration.

    Nov 16, 2027

    in 1 yr 5 mo

  9. Patent 8877248 expires

    Listed drug product patent expiration.

    Nov 16, 2027

    in 1 yr 5 mo

  10. Patent 8877248 expires

    Listed drug product patent expiration.

    Nov 16, 2027

    in 1 yr 5 mo

  11. Patent 8889191 expires

    Listed method-of-use patent (U-1992) expiration.

    Nov 16, 2027

    in 1 yr 5 mo

  12. Patent 8889191 expires

    Listed method-of-use patent (U-106) expiration.

    Nov 16, 2027

    in 1 yr 5 mo

  13. Patent 8992989 expires

    Listed drug product patent expiration.

    Nov 16, 2027

    in 1 yr 5 mo

  14. Patent 8992989 expires

    Listed drug product patent expiration.

    Nov 16, 2027

    in 1 yr 5 mo

  15. Patent 9549940 expires

    Listed drug product patent expiration.

    Nov 16, 2027

    in 1 yr 5 mo

  16. Patent 9549940 expires

    Listed drug product patent expiration.

    Nov 16, 2027

    in 1 yr 5 mo

  17. Patent 9555004 expires

    Listed drug product patent expiration.

    Nov 16, 2027

    in 1 yr 5 mo

  18. Patent 9555004 expires

    Listed drug product patent expiration.

    Nov 16, 2027

    in 1 yr 5 mo

  19. Patent 9622983 expires

    Listed drug product patent expiration.

    Nov 16, 2027

    in 1 yr 5 mo

  20. Patent 9622983 expires

    Listed drug product patent expiration.

    Nov 16, 2027

    in 1 yr 5 mo

  21. Patent 8298576 expires

    Listed drug product patent expiration.

    Apr 04, 2028

    in 1 yr 10 mo

  22. Patent 8298576 expires

    Listed drug product patent expiration.

    Apr 04, 2028

    in 1 yr 10 mo

Pharmaceutical detail

Active ingredient

TOPIRAMATE

Strength

100MG

Dosage form

CAPSULE, EXTENDED RELEASE

Route

ORAL

TE code

AB1

Application

NDA 201635

Product number

003

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (20)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10314790Nov 16, 2027in 1 yr 5 mo
ProductU-1992
10314790Nov 16, 2027in 1 yr 5 mo
ProductU-1675
8298580Nov 16, 2027in 1 yr 5 mo
ProductU-1992
8298580Nov 16, 2027in 1 yr 5 mo
ProductU-106
8663683Nov 16, 2027in 1 yr 5 mo
ProductU-106
8663683Nov 16, 2027in 1 yr 5 mo
ProductU-1992
8877248Nov 16, 2027in 1 yr 5 mo
ProductU-106
8877248Nov 16, 2027in 1 yr 5 mo
ProductU-1992
8889191Nov 16, 2027in 1 yr 5 mo
U-1992
8889191Nov 16, 2027in 1 yr 5 mo
U-106
8992989Nov 16, 2027in 1 yr 5 mo
ProductU-1992
8992989Nov 16, 2027in 1 yr 5 mo
ProductU-1675
9549940Nov 16, 2027in 1 yr 5 mo
ProductU-1992
9549940Nov 16, 2027in 1 yr 5 mo
ProductU-1675
9555004Nov 16, 2027in 1 yr 5 mo
ProductU-1992
9555004Nov 16, 2027in 1 yr 5 mo
ProductU-1675
9622983Nov 16, 2027in 1 yr 5 mo
ProductU-1992
9622983Nov 16, 2027in 1 yr 5 mo
ProductU-1675
8298576Apr 04, 2028in 1 yr 10 mo
ProductU-106
8298576Apr 04, 2028in 1 yr 10 mo
ProductU-1992
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.